

**IPAR**



# Publicly Available Assessment Report for a **Veterinary Medicinal Product**

---

Enro-Sleecol 100 mg/ml oral solution for chickens and turkeys

PRODUCT SUMMARY

EU Procedure number	IE/V/0253/001/DC
Name, strength and pharmaceutical form	Enro-Sleecol 100 mg/ml oral solution for chickens and turkeys
Active substance(s)	Enrofloxacin
Applicant	Krka, d.d., Novo mesto
Legal basis of application	Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of procedure	26 <sup>th</sup> January 2011
Target species	Chickens and turkeys
Indication for use	For the treatment of diseases of the respiratory and alimentary tracts of bacterial or mycoplasmal origin (e.g. pasteurellosis, mycoplasmosis, colibacillosis and salmonellosis), where clinical experience supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
ATCvet code	QJ01MA90
Concerned Member States	BE, DE

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA’s website.

I SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.  
The overall benefit/risk analysis is in favour of granting a marketing authorisation.

II QUALITY ASPECTS

A. Qualitative and Quantitative Particulars

The product contains 100 mg/ml enrofloxacin and the excipients potassium hydroxide, hypromellose, benzyl alcohol and purified water

The container/closure system consists of a 100 ml type III amber glass container with cap and sealing liner with a 25 ml polypropylene dosing cup, a 1 litre high density polyethylene bottle with a 50 ml polypropylene dosing cup, and of a 5 litre high density polyethylene bottle.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

**B.      *Method of Preparation of the Product***

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data for the manufacturing process has been presented in accordance with the relevant European guidelines.

**C.      *Control of Starting Materials***

The active substance is enrofloxacin, an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

*Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies*

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

**D.      *Control on Intermediate Products***

Not applicable.

**E.      *Control Tests on the Finished Product***

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

**F.      *Stability***

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

**G.      *Other Information***

Not applicable.

### **III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)**

**III.A   *Safety Testing***

The application is made in accordance with Article 13(1) of Directive 2001/82/EC, as amended (a generic application).

Exemption from bioequivalence studies (in accordance with paragraph 4(e) of the Guideline for Conduct of Bioequivalence Studies (EMA/CVMP/016)) is accepted because the product is an oral solution containing an active substance in the same concentration as a product approved for use in the same target species, and it contains no inactive substance that can significantly affect the absorption of the active substance.

As the test product is bioequivalent to Baytril 10% Oral Solution, it is accepted that the safety profile (safety to the target species and safety to the user) will be similar to that of the reference product.

A comprehensive environmental risk assessment was presented in support of this application. Based on the data presented, it is accepted that enrofloxacin, when used in accordance with the proposed recommendations for use, does not pose an unacceptable risk to the environment.

### ***III.B Residues Documentation***

#### ***Residue Studies***

No residue depletion studies were conducted.

#### ***MRLs***

Enrofloxacin is listed in Annex I of Council Regulation 2377/90.

The excipients in the formulation are listed in Annex II of Council Regulation 2377/90 or are generally regarded as safe.

#### ***Withdrawal Periods***

As the test product is bioequivalent to Baytril 10% Oral Solution, it is accepted that there will be no difference between products with respect to depletion of residues of enrofloxacin. The proposed withdrawal period for the test product for both chickens and turkeys is the same as that authorised for the reference product in the RMS and can be accepted.

## **IV CLINICAL ASSESSMENT (EFFICACY)**

### ***IV.A Pre-Clinical Studies***

#### ***Pharmacology***

The application is made in accordance with Article 13(1) of Directive 2001/82/EC, as amended (a generic application).

Exemption from bioequivalence studies (in accordance with paragraph 4(e) of the Guideline for Conduct of Bioequivalence Studies (EMA/CVMP/016)) is accepted because the product is an oral solution containing an active substance in the same concentration as a product approved for use in the same target species, and it contains no inactive substance that can significantly affect the absorption of the active substance.

#### ***Tolerance in the Target Species of Animals***

No target animal safety studies were conducted.

Given that:

- The product is an oral dose form,
- Bioequivalence with the reference product Baytril 10% oral solution is accepted
- The toxicological profile of the active substance is well known
- The impurity profile in the formulation is satisfactory
- The excipients are recognised as being safe

the absence of tolerance studies specific to the test product can be accepted.

The information relating to adverse reactions ('None') and overdose ('Do not exceed the recommended dose. In accidental overdose, there is no antidote and treatment should be symptomatic.') included on the SPC for the test product is the same as that included on the SPC of the reference product, Baytril 10% Solution, in Ireland.

### ***Resistance***

Statements relating to appropriate use of fluoroquinolones, in accordance with the requirements of EMEA/CVMP/416168/06 (Reflection Paper on the use of fluoroquinolones in food producing animals - Precautions for use in the SPC regarding prudent use guidance), are included on the SPC.

### ***IV.B Clinical Studies***

The indications and posology proposed for the test product reflect the approved indications and posology for the reference product, Baytril 10% Solution. As the test product is bioequivalent to Baytril 10% Oral Solution, it is accepted that the efficacy profile will be similar to that of the reference product.

## **V OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

## **VI POST-AUTHORISATION ASSESSMENTS**

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the HPRA website.

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

### **Changes:**

**Procedure name:** Type IA C.I.1.A Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a Union referral procedure. IE/V/0253/001/IA/4

**Completion date:** 17/04/2014